Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Mercedes Villarroya, Antonio G García, José Marco-Contelles & Manuela G López. (2007) An update on the pharmacology of galantamine. Expert Opinion on Investigational Drugs 16:12, pages 1987-1998.
Read now
Read now
Articles from other publishers (28)
Zachary G. Baker, Eric Jutkowitz & Joseph E. Gaugler. 2021. Bridging the Family Care Gap. Bridging the Family Care Gap
95
139
.
Chris J. Edgar & Helen Brooker. (2020) Professor Keith Andrew Wesnes (1950 to 2020). Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 12:1.
Crossref
Crossref
Steve Pedrini, Mike Morici & Ralph N. Martins. 2019. Neurodegeneration and Alzheimer's Disease. Neurodegeneration and Alzheimer's Disease
391
442
.
Clara Vila-Castelar, Jenny J Ly, Lillian Kaplan, Kathleen Van Dyk, Jeffrey T Berger, Lucy O Macina, Jennifer L Stewart & Nancy S Foldi. (2019) Attention Measures of Accuracy, Variability, and Fatigue Detect Early Response to Donepezil in Alzheimer’s Disease: A Randomized, Double-blind, Placebo-Controlled Pilot Trial. Archives of Clinical Neuropsychology 34:3, pages 277-289.
Crossref
Crossref
Jeong Jin Park, Seong Hye Choi, SangYun Kim, Ae Young Lee, So Young Moon, Jun Hong Lee, Jae Cheol Kwon, Kyung Won Park, Bon D. Ku, Hyun Jeong Han, Eun‐Joo Kim & Yong S. Shim. (2016) Effect of galantamine on attention in patients with Alzheimer's disease combined with cerebrovascular disease. Geriatrics & Gerontology International 17:10, pages 1661-1666.
Crossref
Crossref
Keith A Wesnes, Cynthia McNamara & Peter Annas. (2016) Norms for healthy adults aged 18–87 years for the Cognitive Drug Research System: An automated set of tests of attention, information processing and memory for use in clinical trials. Journal of Psychopharmacology 30:3, pages 263-272.
Crossref
Crossref
Mizuki Oka, Shutaro Nakaaki, Atsushi Negi, Jun Miyata, Atsuo Nakagawa, Nobutsugu Hirono & Masaru Mimura. (2016) Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease. Psychogeriatrics 16:2, pages 121-134.
Crossref
Crossref
Terry E. Goldberg, Philip D. Harvey, Keith A. Wesnes, Peter J. Snyder & Lon S. Schneider. (2015) Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 1:1, pages 103-111.
Crossref
Crossref
Keith A. Wesnes, Dag Aarsland, Clive Ballard & Elisabet Londos. (2015) Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. International Journal of Geriatric Psychiatry 30:1, pages 46-54.
Crossref
Crossref
Krista L. Lanctôt, Sarah A. Chau, Nathan Herrmann, Lea T. Drye, Paul B. Rosenberg, Roberta W. Scherer, Sandra E. Black, Vijay Vaidya, David L. Bachman & Jacobo E. Mintzer. (2013) Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. International Psychogeriatrics 26:2, pages 239-246.
Crossref
Crossref
Yves Rolland, Christelle Cantet, Philipe de Barreto, Matteo Cesari, Gabor van Kan & Bruno Vellas. (2013) Predictors of decline in walking ability in community-dwelling Alzheimer’s disease patients: Results from the 4-years prospective REAL.FR study. Alzheimer's Research & Therapy 5:5, pages 52.
Crossref
Crossref
Paul S. Foster, Kaylei K. Branch, John C. Witt, Tania Giovannetti, David Libon, Kenneth M. Heilman & Valeria Drago. (2012) Acetylcholinesterase inhibitors reduce spreading activation in dementia. Neuropsychologia 50:8, pages 2093-2099.
Crossref
Crossref
Keith A Wesnes. (2010) Evaluation of techniques to identify beneficial effects of nutrition and natural products on cognitive function. Nutrition Reviews 68, pages S22-S28.
Crossref
Crossref
K. Wesnes, C. Edgar, N. Andreasen, P. Annas, H. Basun, L. Lannfelt, H. Zetterberg, K. Blennow & L. Minthon. (2010) Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer’s disease. Acta Neurologica Scandinavica 122:4, pages 270-277.
Crossref
Crossref
Veronica Lyell, K.W. Ranatunga & Theresa Allain. (2009) CHOLINESTERASE INHIBITORS AND PERIPHERAL NEUROMUSCULAR FUNCTION IN DEMENTIA. Journal of the American Geriatrics Society 57:12, pages 2354-2356.
Crossref
Crossref
Christopher J. Edgar, Edward F. Pace‐Schott & Keith A. Wesnes. (2009) Approaches to measuring the effects of wake‐promoting drugs: a focus on cognitive function. Human Psychopharmacology: Clinical and Experimental 24:5, pages 371-389.
Crossref
Crossref
A. Kadir, T. Darreh-Shori, O. Almkvist, A. Wall, M. Grut, B. Strandberg, A. Ringheim, B. Eriksson, G. Blomquist, B. L?ngstr?m & A. Nordberg. (2008) PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD. Neurobiology of Aging 29:8, pages 1204-1217.
Crossref
Crossref
Frédéric Assal, Gilles Allali, Reto W. Kressig, François R. Herrmann & Olivier Beauchet. (2008) GALANTAMINE IMPROVES GAIT PERFORMANCE IN PATIENTS WITH ALZHEIMER'S DISEASE. Journal of the American Geriatrics Society 56:5, pages 946-947.
Crossref
Crossref
Julien Rouleau & Catherine Guillou. (2008) Synthesis of deuterium‐labelled (−)‐galanthamine. Journal of Labelled Compounds and Radiopharmaceuticals 51:5, pages 236-238.
Crossref
Crossref
Keith A. Wesnes. (2008) Assessing Change in Cognitive Function in Dementia: The Relative Utilities of the Alzheimer’s Disease Assessment Scale – Cognitive Subscale and the Cognitive Drug Research System. Neurodegenerative Diseases 5:3-4, pages 261-263.
Crossref
Crossref
James E. Galvin, Barbara Cornblatt, Paul Newhouse, Sonia Ancoli-Israel, Keith Wesnes, David Williamson, Young Zhu, Karin Sorra & Joan Amatniek. (2008) Effects of Galantamine on Measures of Attention. Alzheimer Disease & Associated Disorders 22:1, pages 30-38.
Crossref
Crossref
Ahmadul Kadir, Taher Darreh-Shori, Ove Almkvist, Anders Wall, Bengt Långström & Agneta Nordberg. (2007) Changes in brain 11C–nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET. Psychopharmacology 191:4, pages 1005-1014.
Crossref
Crossref
Ellen Gorus, Margareta Lambert, Rudi De Raedt & Tony Mets. (2007) The Influence of Galantamine on Reaction Time, Attention Processes, and Performance Variability in Elderly Alzheimer Patients. Journal of Clinical Psychopharmacology 27:2, pages 182-187.
Crossref
Crossref
Elise Rowan, Ian G. McKeith, Brian K. Saxby, John T. O’Brien, David Burn, Urs Mosimann, Jane Newby, Sarah Daniel, Jonathan Sanders & Keith Wesnes. (2007) Effects of Donepezil on Central Processing Speed and Attentional Measures in Parkinson’s Disease with Dementia and Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders 23:3, pages 161-167.
Crossref
Crossref
Elizabeth Coulthard, Victoria Singh-Curry & Masud Husain. (2006) Treatment of attention deficits in neurological disorders. Current Opinion in Neurology 19:6, pages 613-618.
Crossref
Crossref
João Carlos Machado & Paulo Caramelli. (2006) Treatment of dementia: anything new?. Current Opinion in Psychiatry 19:6, pages 575-580.
Crossref
Crossref
Ahmadul Kadir, Ove Almkvist, Anders Wall, Bengt Långström & Agneta Nordberg. (2006) PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer’s disease. Psychopharmacology 188:4, pages 509-520.
Crossref
Crossref
. (2006) Current awareness in geriatric psychiatry. International Journal of Geriatric Psychiatry 21:4, pages 401-408.
Crossref
Crossref